Announcement on Voluntary Disclosure of Initiation of Phase 3 Clinical Trial of GR1802 for Indications for Allergic Rhinitis Treatment

About this update from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Initiation of Phase 3 Clinical Trial of GR1802 for Indications for Allergic Rhinitis TreatmentThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chongqing Genrix Biopharmaceutical Co., Ltd. Class A